HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know
March 05, 2024 at 12:00 PM EST
HC Wainwright & Co. has decided to maintain its Buy rating of Inhibikase Therapeutics (NASDAQ:IKT) and raise its price target from ...